Evidence map›Paper›PMID 40580399›Full record

SynthesisEndocrine2025

Circulating miRNAs in Graves' ophthalmopathy: a systematic review.

Evangelia Syrakouli, Georgios Geropoulos, Styliani Laskou, Elissavet Anestiadou, Argyro Syrakouli, Georgios Koimtzis, Vasileios Geropoulos, Dimitrios Giannis, Konstantinos Sapalidis, Kyriakos Psarras

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Evangelia Syrakouli3rd Department of Surgery, School of Medicine, Aristotle University of Thessaloniki, "AHEPA" University Hospital, Thessaloniki, Greece.
Georgios Geropoulos3rd Department of Surgery, School of Medicine, Aristotle University of Thessaloniki, "AHEPA" University Hospital, Thessaloniki, Greece. georgios.geropoulos@nhs.net.
Styliani Laskou3rd Department of Surgery, School of Medicine, Aristotle University of Thessaloniki, "AHEPA" University Hospital, Thessaloniki, Greece.
Elissavet Anestiadou4th Department of Surgery, School of Medicine, Aristotle University of Thessaloniki, General Hospital "George Papanikolaou", Thessaloniki, Greece.
Argyro SyrakouliDepartment of Pediatrics, School of Medicine, University of Thessaly, University Hospital of Larissa, Larissa, Greece.
Georgios KoimtzisDepartment of Surgery, University Hospital of Wales, Cardiff and Vale University Health Board, Cardiff, UK.
Vasileios Geropoulos3rd Department of Surgery, School of Medicine, Aristotle University of Thessaloniki, "AHEPA" University Hospital, Thessaloniki, Greece.
Dimitrios GiannisDepartment of Surgery, Flushing Hospital Medical Center (MediSys), Flushing, Queens, NY, USA.
Konstantinos Sapalidis3rd Department of Surgery, School of Medicine, Aristotle University of Thessaloniki, "AHEPA" University Hospital, Thessaloniki, Greece.
Kyriakos Psarras3rd Department of Surgery, School of Medicine, Aristotle University of Thessaloniki, "AHEPA" University Hospital, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGraves' ophthalmopathy (GO) affects up to 40% of patients with Graves' disease. Identifying biomarkers that predict which patients with Graves' disease may develop GO or determining which GO patients will respond to conservative treatment is critical for improving targeted management. This study aims to investigate potential circulating miRNAs in serum or plasma that may serve as biomarkers for the diagnosis and prognosis of GO.

methodsA systematic literature search was conducted in the MEDLINE, EMBASE, and Cochrane databases. Studies involving human participants with or without GO that assessed miRNA expression levels in serum, plasma, or CD4

resultsEleven studies met the inclusion criteria. A total of 6567 miRNAs were analyzed in the serum, plasma, or CD4

conclusionMiRNAs hold promise as biomarkers for the early diagnosis, prognosis, and prediction of response to glucocorticoid therapy in GO patients. There is a correlation between miRNA expression in serum or plasma and the presence, activity, and response to glucocorticoid therapy in GO patients. However, further clinical studies are necessary to validate the predictive value of miRNAs as biomarkers in clinical practice.

Indexed as

Circulating MicroRNAGraves OphthalmopathyMicroRNAsBiomarkersHumansPrognosisBiomarkersCirculating MicroRNAMicroRNAsBiomarkersCirculating miRNAsGraves’ Ophthalmopathy (GO)

Identifiers

PMID40580399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.